<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Ramani B</submitter><funding>NINDS NIH HHS</funding><pubmed_abstract>Polyglutamine (polyQ) diseases, including Huntington's disease and several spinocerebellar ataxias, are caused by abnormally expanded CAG nucleotide repeats, which encode aggregation-prone polyQ tracts. Substantial prior evidence supports a pathogenic role for polyQ protein misfolding and aggregation, with molecular chaperones showing promise in suppressing disease phenotypes in cellular and animal models. In this study, we developed a FRET-based reporter system that models polyQ aggregation in human cells and used it to perform a high-throughput CRISPR interference screen targeting all known molecular chaperones. This screen identified as a strong suppressor of polyQ aggregation the Hsp40 co-chaperone DNAJC7, which has previously been shown to modify aggregation of other disease proteins </pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2025.08.10.669490</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12363876</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Hsp40 co-chaperone DNAJC7 modifies polyglutamine but not polyglycine aggregation.</pubmed_title><pmcid>PMC12363876</pmcid><funding_grant_id>K08 NS133300</funding_grant_id><funding_grant_id>R25 NS070680</funding_grant_id><pubmed_authors>Ramani B</pubmed_authors><pubmed_authors>Ehsani K</pubmed_authors><pubmed_authors>Kampmann M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Hsp40 co-chaperone DNAJC7 modifies polyglutamine but not polyglycine aggregation.</name><description>Polyglutamine (polyQ) diseases, including Huntington's disease and several spinocerebellar ataxias, are caused by abnormally expanded CAG nucleotide repeats, which encode aggregation-prone polyQ tracts. Substantial prior evidence supports a pathogenic role for polyQ protein misfolding and aggregation, with molecular chaperones showing promise in suppressing disease phenotypes in cellular and animal models. In this study, we developed a FRET-based reporter system that models polyQ aggregation in human cells and used it to perform a high-throughput CRISPR interference screen targeting all known molecular chaperones. This screen identified as a strong suppressor of polyQ aggregation the Hsp40 co-chaperone DNAJC7, which has previously been shown to modify aggregation of other disease proteins </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-07-11T03:16:39.232Z</modification><creation>2026-07-11T03:08:31.708Z</creation></dates><accession>S-EPMC12363876</accession><cross_references><pubmed>40832276</pubmed><doi>10.1101/2025.08.10.669490</doi></cross_references></HashMap>